Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 693 Billion JPY | -11.57% |
| 2022 | 783.69 Billion JPY | 18.45% |
| 2021 | 661.61 Billion JPY | 28.85% |
| 2020 | 513.48 Billion JPY | 22.22% |
| 2019 | 420.11 Billion JPY | 32.55% |
| 2018 | 316.94 Billion JPY | 13.18% |
| 2017 | 280.02 Billion JPY | 14.84% |
| 2016 | 243.83 Billion JPY | -5.71% |
| 2015 | 258.6 Billion JPY | 6.41% |
| 2014 | 243.03 Billion JPY | 2.69% |
| 2013 | 236.67 Billion JPY | 5.9% |
| 2012 | 223.49 Billion JPY | 3.46% |
| 2011 | 216.01 Billion JPY | -0.5% |
| 2010 | 217.09 Billion JPY | -8.05% |
| 2009 | 236.09 Billion JPY | 18.1% |
| 2008 | 199.9 Billion JPY | -3.66% |
| 2007 | 207.51 Billion JPY | 7.51% |
| 2006 | 193.02 Billion JPY | -7.07% |
| 2005 | 207.7 Billion JPY | 13.42% |
| 2004 | 183.13 Billion JPY | 22.98% |
| 2003 | 148.91 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 163.99 Billion JPY | -9.77% |
| 2024 Q2 | 227.97 Billion JPY | 39.01% |
| 2023 Q3 | 179.64 Billion JPY | 2.21% |
| 2023 Q4 | 181.75 Billion JPY | 1.18% |
| 2023 Q1 | 160.91 Billion JPY | -28.67% |
| 2023 FY | 693 Billion JPY | -11.57% |
| 2023 Q2 | 175.75 Billion JPY | 9.22% |
| 2022 Q4 | 225.58 Billion JPY | 44.43% |
| 2022 Q2 | 155.78 Billion JPY | -36.7% |
| 2022 Q1 | 246.13 Billion JPY | 16.26% |
| 2022 FY | 783.69 Billion JPY | 18.45% |
| 2022 Q3 | 156.18 Billion JPY | 0.26% |
| 2021 Q2 | 153.35 Billion JPY | 35.14% |
| 2021 Q1 | 113.48 Billion JPY | -17.86% |
| 2021 FY | 661.61 Billion JPY | 28.85% |
| 2021 Q4 | 211.71 Billion JPY | 15.64% |
| 2021 Q3 | 183.07 Billion JPY | 19.38% |
| 2020 Q1 | 118.15 Billion JPY | 4.32% |
| 2020 Q3 | 139.04 Billion JPY | 17.71% |
| 2020 FY | 513.48 Billion JPY | 22.22% |
| 2020 Q4 | 138.16 Billion JPY | -0.63% |
| 2020 Q2 | 118.12 Billion JPY | -0.02% |
| 2019 Q3 | 114.54 Billion JPY | 12.38% |
| 2019 Q2 | 101.92 Billion JPY | 12.77% |
| 2019 FY | 420.11 Billion JPY | 32.55% |
| 2019 Q1 | 90.38 Billion JPY | 5.69% |
| 2019 Q4 | 113.26 Billion JPY | -1.12% |
| 2018 Q3 | 75.37 Billion JPY | 4.03% |
| 2018 Q4 | 85.51 Billion JPY | 13.45% |
| 2018 Q2 | 72.45 Billion JPY | -13.33% |
| 2018 Q1 | 83.59 Billion JPY | 5.97% |
| 2018 FY | 316.94 Billion JPY | 13.18% |
| 2017 Q4 | 78.89 Billion JPY | 13.01% |
| 2017 Q2 | 67.03 Billion JPY | 4.25% |
| 2017 Q1 | 64.3 Billion JPY | -2.84% |
| 2017 FY | 280.02 Billion JPY | 14.84% |
| 2017 Q3 | 69.8 Billion JPY | 4.14% |
| 2016 FY | 243.83 Billion JPY | -5.71% |
| 2016 Q3 | 55.15 Billion JPY | -13.54% |
| 2016 Q2 | 63.79 Billion JPY | 8.65% |
| 2016 Q1 | 58.71 Billion JPY | -15.59% |
| 2016 Q4 | 66.18 Billion JPY | 20.0% |
| 2015 FY | 258.6 Billion JPY | 6.41% |
| 2015 Q4 | 69.55 Billion JPY | 5.21% |
| 2015 Q3 | 66.1 Billion JPY | 3.95% |
| 2015 Q2 | 63.59 Billion JPY | 7.17% |
| 2015 Q1 | 59.34 Billion JPY | -11.34% |
| 2014 Q3 | 56.69 Billion JPY | 11.49% |
| 2014 Q4 | 66.93 Billion JPY | 18.05% |
| 2014 FY | 243.03 Billion JPY | 2.69% |
| 2014 Q1 | 68.54 Billion JPY | 8.23% |
| 2014 Q2 | 50.85 Billion JPY | -25.81% |
| 2013 Q4 | 63.33 Billion JPY | 4.4% |
| 2013 Q3 | 60.66 Billion JPY | -3.78% |
| 2013 FY | 236.67 Billion JPY | 5.9% |
| 2013 Q1 | 49.63 Billion JPY | -28.2% |
| 2013 Q2 | 63.04 Billion JPY | 27.02% |
| 2012 FY | 223.49 Billion JPY | 3.46% |
| 2012 Q1 | 50.64 Billion JPY | -8.51% |
| 2012 Q4 | 69.12 Billion JPY | 35.98% |
| 2012 Q3 | 50.83 Billion JPY | -3.87% |
| 2012 Q2 | 52.88 Billion JPY | 4.42% |
| 2011 Q4 | 55.35 Billion JPY | 3.93% |
| 2011 FY | 216.01 Billion JPY | -0.5% |
| 2011 Q3 | 53.26 Billion JPY | -6.19% |
| 2011 Q1 | 50.61 Billion JPY | -16.5% |
| 2011 Q2 | 56.77 Billion JPY | 12.17% |
| 2010 Q4 | 60.62 Billion JPY | 10.94% |
| 2010 Q2 | 55.81 Billion JPY | 21.29% |
| 2010 Q1 | 46.01 Billion JPY | -33.96% |
| 2010 FY | 217.09 Billion JPY | -8.05% |
| 2010 Q3 | 54.64 Billion JPY | -2.1% |
| 2009 Q1 | 50.95 Billion JPY | 0.0% |
| 2009 Q3 | 58.58 Billion JPY | 3.02% |
| 2009 Q4 | 69.68 Billion JPY | 18.94% |
| 2009 FY | 236.09 Billion JPY | 18.1% |
| 2009 Q2 | 56.86 Billion JPY | 11.61% |
| 2008 FY | 199.9 Billion JPY | -3.66% |
| 2007 FY | 207.51 Billion JPY | 7.51% |
| 2006 FY | 193.02 Billion JPY | -7.07% |
| 2005 FY | 207.7 Billion JPY | 13.42% |
| 2004 FY | 183.13 Billion JPY | 22.98% |
| 2003 FY | 148.91 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | -1897.537% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -1919.669% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -2199.439% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -6167106.55% |
| Novartis AG | 34.18 Billion USD | -1927.053% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -93112.378% |